<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086081</url>
  </required_header>
  <id_info>
    <org_study_id>DUPLICATE-ISAR-REACT</org_study_id>
    <nct_id>NCT05086081</nct_id>
  </id_info>
  <brief_title>Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data</brief_title>
  <official_title>Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators are building an empirical evidence base for real world data through large-scale&#xD;
      replication of randomized controlled trials. The investigators' goal is to understand for&#xD;
      what types of clinical questions real world data analyses can be conducted with confidence&#xD;
      and how to implement such studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE&#xD;
      initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical&#xD;
      School. It is intended to replicate, as closely as possible in healthcare insurance claims&#xD;
      data, the trial listed below/above. Although many features of the trial cannot be directly&#xD;
      replicated in healthcare claims, key design features, including outcomes, exposures, and&#xD;
      inclusion/exclusion criteria, were selected to proxy those features from the trial.&#xD;
      Randomization is also not replicable in healthcare claims data but was proxied through a&#xD;
      statistical balancing of measured covariates through standard practice. Investigators assume&#xD;
      that the RCT provides the reference standard treatment effect estimate and that failure to&#xD;
      replicate RCT findings is indicative of the inadequacy of the healthcare claims data for&#xD;
      replication for a range of possible reasons and does not provide information on the validity&#xD;
      of the original RCT finding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2020</start_date>
  <completion_date type="Actual">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">September 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative hazard of composite of death, myocardial infarction, or stroke at 1 year after randomization</measure>
    <time_frame>Through study completion or censoring, up to 12 months</time_frame>
    <description>Claims-based algorithm: Relative hazard of composite of death, myocardial infarction, or stroke at 1 year after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative hazard of hospital admission for MI, hospital admission for stroke, or death</measure>
    <time_frame>Through study completion or censoring, up to 12 months</time_frame>
    <description>Claims-based algorithm: Relative hazard of hospital admission for MI, hospital admission for stroke, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative hazard of major bleeding</measure>
    <time_frame>Through study completion or censoring, up to 12 months</time_frame>
    <description>Claims-based algorithm: relative hazard of major bleeding</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">28389</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <description>Reference group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <description>Exposure group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg</intervention_name>
    <description>Any ticagrelor dispensing claim is used as the exposure group</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 10mg</intervention_name>
    <description>Any prasugrel dispensing claim is used as the reference group</description>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will involve a new user, parallel group, retrospective cohort study design&#xD;
        comparing ticagrelor 90 mg twice daily to prasugrel 10 mg daily. The patients will be&#xD;
        required to have continuous enrollment during the baseline period of 180 days before&#xD;
        initiation of ticagrelor or prasugrel (index date). We will restrict the analyses to&#xD;
        patients with an acute coronary syndrome, with or without ST-segment elevation, who were&#xD;
        scheduled to undergo coronary angiography.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
        Please see https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for&#xD;
        full code and algorithm definitions.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalization for unstable angina or acute MI AND age &gt;= 18 years Days [ACS&#xD;
             admission]&#xD;
&#xD;
          -  STEMI OR NSTEMI/unstable angina (during admission) + 1 of the following&#xD;
&#xD;
               -  &gt;= 60 years old Days [ACS]&#xD;
&#xD;
               -  &gt;= 3 risk factors for coronary artery disease&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Chronic renal disease&#xD;
&#xD;
               -  Carotid stenosis &gt;= 50% or cerebral revascularization&#xD;
&#xD;
               -  Peripheral artery disease Days [-365, ACS]&#xD;
&#xD;
               -  Aspirin use&#xD;
&#xD;
               -  Angina Days [-7, ACS]&#xD;
&#xD;
               -  Prior MI or CABG any time prior&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute complication PCI Days [-30, ACS admission]&#xD;
&#xD;
          -  History of any stroke or TIA Days [all available data, 0]&#xD;
&#xD;
          -  Intracranial neoplasm, intracranial AVM, intracranial neoplasm Days [-180, 0]&#xD;
&#xD;
          -  Active bleeding Days [-180, 0]&#xD;
&#xD;
          -  Platelet count &lt; 100.000/uL Days [-180, 0]&#xD;
&#xD;
          -  Anemia (hemoglobin &lt; 10 g/dL) Days [-180, 0]&#xD;
&#xD;
          -  Chronic renal insufficiency requiring dialysis Days [-180, 0]&#xD;
&#xD;
          -  Moderate to severe hepatic dysfunction Days [-180, 0]&#xD;
&#xD;
          -  Increased risk of bradycardia events Days [-180, 0]&#xD;
&#xD;
          -  Life expectancy, 1 year Days [-180, 0]&#xD;
&#xD;
          -  Pregnancy Days [-180, 0]&#xD;
&#xD;
          -  Concomitant therapy CYP3A inhibitors, CYP3A substrates, or strong CYP3A inducers Days&#xD;
             [-14, 0]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Franklin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shirley Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jessica Franklin</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 3, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT05086081/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

